NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
106 trialsNCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06934889 2026-03-30
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05739942 2026-02-03
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis
Phase 1 Active not recruiting
NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05236036 2026-01-14
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT05083754 2026-01-09
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT04474353 2025-12-26
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
Phase 1 Completed
NCT06410248 2025-12-19
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT03587038 2025-12-10
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
University of Oklahoma
Phase 1 Active not recruiting
NCT04900792 2025-12-03
XACT-Fe-GBM-01
University of Iowa
Phase 1 Active not recruiting
NCT03224104 2025-11-26
STEAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT07223034 2025-11-04
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04555577 2025-10-29
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03535350 2025-09-30
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT05190315 2025-09-02
Chlorpromazine and Standard of Care in Glioblastoma
University of Iowa
Phase 1 Completed
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT04477200 2025-06-29
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
Phase 1 Active not recruiting
NCT05879367 2025-06-25
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
Phase 1 Recruiting
NCT01430351 2025-05-07
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05769660 2025-03-10
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
BeyondBio Inc.
Phase 1 Recruiting
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT04397679 2025-01-15
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01849146 2025-01-09
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01752491 2024-12-20
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
University of Iowa
Phase 1 Completed
NCT03232424 2024-11-18
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Hackensack Meridian Health
Phase 1 Completed
NCT00102648 2024-10-17
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04324840 2024-07-26
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
Celgene
Phase 1 Terminated
NCT02880410 2024-04-12
FLAG
Monteris Medical
Phase 1 Terminated
NCT03705351 2024-03-04
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
Phase 1 Terminated
NCT02168270 2023-11-24
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT02530502 2023-11-18
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Terminated
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT01269424 2023-03-02
BG & TMZ Therapy of Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01700569 2023-02-21
FOLAGLI
Institut Cancerologie de l'Ouest
Phase 1 Terminated
NCT03867123 2023-02-21
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
Phase 1 Completed
NCT05700955 2023-01-26
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
Phase 1 Unknown
NCT04385173 2022-12-28
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT02864368 2022-06-09
PERFORMANCE
Duke University
Phase 1 Terminated
NCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed